Chronic migraine treatment: from OnabotulinumtoxinA onwards.
作者： Andrea Negro , Martina Curto , Luana Lionetto , Maria Adele Giamberardino , Paolo Martelletti
DOI: 10.1080/14737175.2016.1200973
关键词: Migraine 、 Alternative medicine 、 Medication overuse 、 Chronic Migraine 、 Acute pain 、 Internal medicine 、 Calcitonin gene-related peptide 、 Quality of life 、 Anesthesia 、 Natural course 、 Medicine
摘要: ABSTRACTIntroduction: WHO ranks migraine as the 6th highest cause of disability worldwide when considered alone, and 3rd medication overuse headache (MOH) is included. Migraine an episodic disorder but in its natural course, frequency could progressively increase evolve to a chronic form. More than 50% patients show acute pain medications which linked development MOH.Areas covered: Our goal review existing data on OnabotulinoumtoxinA CGRP-targeting drugs such anti-CGRP monoclonal antibodies, one most promising under development. The research bibliographic databases has included only published peer-reviewed articles from indexed journals.Expert commentary: To date, real-life studies are supporting OnabotulinumtoxinA treatment migraine. Additionally, mAbs showed good efficacy safety recent RCTs may soon contribute improve quality life suf...
sci-hub.se 参考文章(112)
L. Grazzi, S. Usai, Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience Neurological Sciences. ,vol. 36, pp. 33- 35 ,(2015) , 10.1007/S10072-015-2140-2
Eric L Moore, Christopher A Salvatore, Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine. British Journal of Pharmacology. ,vol. 166, pp. 66- 78 ,(2012) , 10.1111/J.1476-5381.2011.01633.X
Stephanie Wrobel Goldberg, Stephen David Silberstein, Targeting CGRP: A New Era for Migraine Treatment CNS Drugs. ,vol. 29, pp. 443- 452 ,(2015) , 10.1007/S40263-015-0253-Z
Ninan T. Mathew, Pathophysiology of Chronic Migraine and Mode of Action of Preventive Medications Headache. ,vol. 51, pp. 84- 92 ,(2011) , 10.1111/J.1526-4610.2011.01955.X
Timothy J. Steiner, Gretchen L. Birbeck, Rigmor H. Jensen, Zaza Katsarava, Lars J. Stovner, Paolo Martelletti, Headache disorders are third cause of disability worldwide Journal of Headache and Pain. ,vol. 16, pp. 58- 58 ,(2015) , 10.1186/S10194-015-0544-2
Stephen Silberstein, Robert Lenz, Cen Xu, Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know Headache. ,vol. 55, pp. 1171- 1182 ,(2015) , 10.1111/HEAD.12642
Lars Edvinsson, CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment British Journal of Clinical Pharmacology. ,vol. 80, pp. 193- 199 ,(2015) , 10.1111/BCP.12618
Dan Levy, Migraine Pain and Nociceptor Activation-Where Do We Stand? Headache: The Journal of Head and Face Pain. ,vol. 50, pp. 909- 916 ,(2010) , 10.1111/J.1526-4610.2010.01670.X
J Zeller, K T Poulsen, J E Sutton, Y N Abdiche, S Collier, R Chopra, C A Garcia, J Pons, A Rosenthal, D L Shelton, CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat British Journal of Pharmacology. ,vol. 155, pp. 1093- 1103 ,(2009) , 10.1038/BJP.2008.334
L Edvinsson, CGRP blockers in migraine therapy: where do they act? British Journal of Pharmacology. ,vol. 155, pp. 967- 969 ,(2009) , 10.1038/BJP.2008.346